GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Estrella Immunopharma Inc (NAS:ESLA) » Definitions » Other Current Receivables

Estrella Immunopharma (Estrella Immunopharma) Other Current Receivables : $0.00 Mil (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Estrella Immunopharma Other Current Receivables?

Estrella Immunopharma's Other Current Receivables for the quarter that ended in Dec. 2023 was $0.00 Mil.


Estrella Immunopharma Other Current Receivables Historical Data

The historical data trend for Estrella Immunopharma's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Estrella Immunopharma Other Current Receivables Chart

Estrella Immunopharma Annual Data
Trend Jun21
Other Current Receivables
-

Estrella Immunopharma Quarterly Data
Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Sep23 Dec23
Other Current Receivables Get a 7-Day Free Trial - - - - -

Estrella Immunopharma Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.


Estrella Immunopharma Other Current Receivables Related Terms

Thank you for viewing the detailed overview of Estrella Immunopharma's Other Current Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Estrella Immunopharma (Estrella Immunopharma) Business Description

Traded in Other Exchanges
N/A
Address
5858 Horton Street, Suite 170, Emeryville, CA, USA, 94608
Estrella Immunopharma Inc is a preclinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer.

Estrella Immunopharma (Estrella Immunopharma) Headlines

No Headlines